Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | EYA2 | O00167 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597699 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL2597828 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL3001043 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL24732403 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL2995896 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL24732405 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL9793636 | 0.96 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8207533 | 0.96 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1275068 | 0.96 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| SCHEMBL19962167 | 0.94 | TDP1 (0.42) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998048844-A2 | ION PARIS, METHOD FOR THE PRODUCTION AND USE THEREOF AS CONTRAST AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-11-05 | — | — | WO | claimed |
| WO-2025106926-A1 | CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF | Praxis Biotech LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025106939-A1 | CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF | Praxis Biotech LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4448544-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| EP-4373529-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2024-05-29 | — | — | EP | disclosed |
| EP-4274836-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| US-20100068151-A1 | MULTIMODALITY MOLECULAR IMAGING WITH THERAPEUTIC CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-18 | — | — | US | disclosed |
| EP-1846042-A2 | CONJUGATES FOR DUAL IMAGING AND RADIOCHEMOTHERAPY: COMPOSITION, MANUFACTURING, AND APPLICATIONS | Board of Regents, The University of Texas System (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070196275-A1 | Diagnostic Imaging Compositions, Their Methods Of Synthesis And Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-23 | — | — | US | disclosed |
| US-7214545-B2 | Element-coded affinity tags | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070071673-A1 | Trifunctional reagent for conjugation to a biomolecule | MITRA MEDICAL TECHNOLOGY AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070071673-A1 | Trifunctional reagent for conjugation to a biomolecule | MITRA MEDICAL TECHNOLOGY AB (SE) | 2007-03-29 | — | — | US | disclosed |
| WO-2006074272-A2 | CONJUGATES FOR DUAL IMAGING AND RADIOCHEMOTHERAPY: COMPOSITION, MANUFACTURING, AND APPLICATIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1389090-A2 | DIAGNOSTIC IMAGING COMPOSITIONS, THEIR METHODS OF SYNTHESIS AND USE | Board of Regents, The University of Texas System (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030003048-A1 | Diagnostic imaging compositions, their methods of synthesis and use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-02 | — | — | US | disclosed |
| WO-2002087498-A2 | DIAGNOSTIC IMAGING COMPOSITIONS, THEIR METHODS OF SYNTHESIS AND USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070071673-A1 | Trifunctional reagent for conjugation to a biomolecule | UACA, TNFSF11, CD40 | TDP1 3549/4885EYA2 1832/4885APP 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.